SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (11911)12/11/2018 11:22:56 AM
From: scaram(o)uche  Respond to of 12215
 
>> what is/was expected from +$3B EV program <<

OK, not going to argue with that.

But it's no longer that company. It's now a company headed to phase III with MC:cash ~ 4. So launching with two sites open in Q1 would be delicious.



To: Miljenko Zuanic who wrote (11911)12/11/2018 12:19:45 PM
From: tuck  Read Replies (1) | Respond to of 12215
 
MDGL: Traveling, so don't have time to do anything other than throw this thought out: What are the parallels between INCY at MDGL at this stage? Seems like Friedman did well with this process at INCY. Should we trust him to do it well here despite possible indicators to the contrary?

Cheers, Tuck



To: Miljenko Zuanic who wrote (11911)12/11/2018 3:24:34 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 12215
 
mgl 3745 of course also came from Roche. Safe to presume that there's no patent advantage?